Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bosiqing vs Abilify (Aripiprazole)
NCT03232710Phase 1Unknown
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Jun 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aripiprazole in schizophrenia and bipolar disorder (BD) (5 arms), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 54 and Area Under the Curve at Day 54. Status: unknown.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT03232710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232710.